Biomarker Negativity At Issue In Pfizer Bid To Broaden Talzenna CRPC Claim

 
• By Bridget Silverman
  
Pfizer wants Talzenna for first-line castration-resistant prostate cancer unrestricted by biomarkers, but the FDA questioned the study design behind the application ahead of an advisory committee review. (Shutterstock)

More from US Advisory Committees

More from Product Reviews